J Cancer 2017; 8(2):220-226. doi:10.7150/jca.16850 This issue Cite

Research Paper

The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma

Ming Yao1,2*, Yuan-Yuan Shang2,3*, Zhi-Wei Zhou2, Yin-Xue Yang4, Yin-Sheng Wu1, Li-Feng Guan1, Xin-Yu Wang2,5, Shu-Feng Zhou2✉, Xi Wei6✉

1. Department of Burns and Plastic Surgery, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China.
2. Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.
3. Department of Dermatology, General Hospital, Ningxia Medical University;
4. Department of Colorectal Surgery, General Hospital, Ningxia Medical University;
5. Department of Pharmacy, General Hospital, Ningxia Medical University, Yinchuan;
6. Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
* These authors Ming Yao and Yuan-Yuan Shang contributed equally to this work.

Citation:
Yao M, Shang YY, Zhou ZW, Yang YX, Wu YS, Guan LF, Wang XY, Zhou SF, Wei X. The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma. J Cancer 2017; 8(2):220-226. doi:10.7150/jca.16850. https://www.jcancer.org/v08p0220.htm
Other styles

File import instruction

Abstract

Cutaneous squamous cell carcinoma (cSCC) contributes to one of most common types of skin cancer. Epidermal growth factor receptor (EGFR) activation has been investigated to be associated with the development of cSCC. Lapatinib is an inhibitor targeting HER2/neu and EGFR pathway. We found that lapatinib can inhibit proliferation by enhancing apoptosis of human cSCC cell lines. The cSCC cell cycle distribution could be arrested in G2/M phase after lapatinib treatment. In the in vitro experiment, we found that lapatinib interrupted PI3K/AKT/mTOR signaling pathway in human cSCC cells. Furthermore, lapatinib could suppress epithelial to mesenchymal transition (EMT) via Wnt/ErK/PI3K-AKT signaling pathway to represent a promising anticancer drug for cSCC treatment.

Keywords: Lapatinib, cutaneous squamous cell carcinoma (cSCC), proliferation, epithelial to mesenchymal transition.


Citation styles

APA
Yao, M., Shang, Y.Y., Zhou, Z.W., Yang, Y.X., Wu, Y.S., Guan, L.F., Wang, X.Y., Zhou, S.F., Wei, X. (2017). The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma. Journal of Cancer, 8(2), 220-226. https://doi.org/10.7150/jca.16850.

ACS
Yao, M.; Shang, Y.Y.; Zhou, Z.W.; Yang, Y.X.; Wu, Y.S.; Guan, L.F.; Wang, X.Y.; Zhou, S.F.; Wei, X. The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma. J. Cancer 2017, 8 (2), 220-226. DOI: 10.7150/jca.16850.

NLM
Yao M, Shang YY, Zhou ZW, Yang YX, Wu YS, Guan LF, Wang XY, Zhou SF, Wei X. The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma. J Cancer 2017; 8(2):220-226. doi:10.7150/jca.16850. https://www.jcancer.org/v08p0220.htm

CSE
Yao M, Shang YY, Zhou ZW, Yang YX, Wu YS, Guan LF, Wang XY, Zhou SF, Wei X. 2017. The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma. J Cancer. 8(2):220-226.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image